$3.2 Billion Investment Will Employ 1,400 People by 2031
HOLLY SPRINGS, N.C., September 24, 2025 – FUJIFILM Biotechnologies today marked a major milestone with the grand opening of its commercial-scale cell culture manufacturing facility in Holly Springs, North Carolina. Representing a $3.2 billion investment, the new site is one of the largest of its kind in North America and will employ 1,400 people by 2031.
The first phase of the project launches with 8 x 20,000-liter mammalian cell culture bioreactors, providing robust drug product and drug substance manufacturing capabilities. A second phase, announced in 2024, will double production with an additional 8 x 20,000-liter bioreactors.
“Our new U.S. commercial-scale manufacturing hub underscores Fujifilm’s commitment to advancing life sciences and ensuring a stable supply chain for our partners,” said Toshihisa Iida, corporate vice president and general manager of Life Sciences Strategy Headquarters and Bio CDMO Division, FUJIFILM Corporation.
Economic Impact in North Carolina
The project is expected to add $4.7 billion to the state’s economy over the next decade, further establishing North Carolina as a biotech leader.
“Fujifilm is investing in the workforce of today and tomorrow,” said Governor Josh Stein. “This project not only creates 1,400 high-quality jobs but also strengthens our reputation as a premier hub for biotechnology and advanced manufacturing.”
Community Growth and Workforce Development
With more than 680 employees already on-site, FUJIFILM Biotechnologies plans to reach 750 by the end of 2025 and scale to 1,400 by 2031. The company is partnering with regional universities, colleges, and workforce training centers to ensure a steady pipeline of skilled talent.
“This is a historic milestone for Holly Springs,” said Mayor Sean Mayefskie. “At full buildout, FUJIFILM Biotechnologies will become our largest employer, boosting our local economy and attracting new businesses to the region.”
Innovation and Sustainability
FUJIFILM Biotechnologies implemented its kojoX™ modular facility design, reducing design time by 70% and expediting delivery of life-saving medicines. The facility will also offset 100% of carbon emissions from electricity consumption through renewable energy credits, supporting Fujifilm’s commitment to carbon neutrality by 2040.
“Delivering this world-class facility in under five years reflects the dedication of our team and partners,” said Lars Petersen, president and CEO of FUJIFILM Biotechnologies. “This site helps address the global demand for life-changing medicines while advancing sustainable biomanufacturing.”
Global Significance
As part of FUJIFILM Corporation’s $8 billion global investment in CDMO operations, the Holly Springs site joins a network of advanced facilities worldwide. Leaders from Johnson & Johnson and Regeneron highlighted the project’s role in securing U.S. biomanufacturing capacity and supporting pharmaceutical innovation.
